Zoledronic acid medac (zoledronic acid)
Generic
- Region
- 🇪🇺 EU
- Active substance
- zoledronic acid
- Company
- medac Gesellschaft für klinische Spezialpräparate mbH
- Status
- Withdrawn
- Therapeutic area
- Fractures, Bone; Cancer
- CHMP opinion
- Thu 24 May 2012
- EU approval
- Fri 03 Aug 2012
- Designations
- Generic
- Application
- EMEA/H/C/002359
- ATC
- M05BA08
- Official record
- www.ema.europa.eu
Indication
Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Zoledronic acid Mylan Authorised · Mylan Pharmaceuticals Limited
- 🇪🇺 Zoledronic acid Teva Authorised · Teva B.V.
- 🇪🇺 Zoledronic acid Actavis Withdrawn · Actavis Group PTC ehf
- 🇪🇺 Zoledronic Acid Hospira Withdrawn · Pfizer Europe MA EEIG
- 🇪🇺 Aclasta Authorised · Sandoz Pharmaceuticals d.d.
- 🇪🇺 Zoledronic Acid Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Zometa Authorised · Phoenix Labs Unlimited Company
- 🇪🇺 Zoledronic acid Teva Pharma Withdrawn · Teva B.V.
- 🇪🇺 Zoledronic acid Teva Generics Withdrawn · Teva Generics B.V
Follow Zoledronic acid medac
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.